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2072 Ohue et al Journal of Thoracic Oncology Vol. 14 No. 12Methods: We conducted a prospective study to explore
whether serum antibody against NY-ESO-1 and/or XAGE1
cancer-testis antigens predicted primarily good clinical
response and secondarily long survival with anti–PD-1
therapy for NSCLC. The serum antibody was detected by
enzyme-linked immunosorbent assay, and tumor immune
microenvironment and mutation burden were analyzed by
immunohistochemistry and next-generation sequencing.
Results: In the discovery cohort (n ¼ 13), six antibody-
positive NSCLC cases responded to anti–PD-1 therapy
(two complete and four partial responses), whereas seven
antibody-negative NSCLC cases did not. Antibody positivity
was associated with good response and survival, regardless
of tumor programmed death ligand 1 (PD-L1) expression,
mutation burden, and CD8þ T-cell infiltration. In the vali-
dation cohort (n ¼ 75), 17 antibody-positive NSCLC cases
responded well to anti–PD-1 therapy as compared with 58
negative NSCLC cases (objective response rate 65% versus
19%, p ¼ 0.0006) and showed significantly prolonged
progression-free survival and overall survival. Antibody ti-
ters highly correlated with tumor reduction rates. In the
multivariate analysis, response biomarkers were tumor
programmed death ligand 1 expression and antibody posi-
tivity, and only antibody positivity was a significantly better
predictive biomarker of progression-free survival (hazard
ratio ¼ 0.4, p ¼ 0.01) and overall survival (hazard ratio ¼
0.2, p ¼ 0.004).
Conclusions: Our results suggest that NY-ESO-1 and/or
XAGE1 serum antibodies are useful biomarkers for pre-
dicting clinical benefits in anti–PD-1 therapy for NSCLC and
probably for other cancers.
 2019 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Lung cancer is the leading cause of death from
cancer worldwide.1 Most lung cancers, especially
NSCLC, are diagnosed in the advanced stages and are
resistant to conventional chemotherapy, resulting in
poor prognosis. Recently, immunotherapy using
immune-checkpoint inhibitors has prolonged NSCLC
patient survival.2 Programmed cell death-1 (PD-1) of
an immune-checkpoint molecule is expressed on acti-
vated CD8þ T cells and binds to programmed death
ligand 1 (PD-L1) on tumor cells, resulting in T-cell
exhaustion.3 Therapeutic antibodies (Abs) for PD-1,
nivolumab and pembrolizumab, inhibit this binding
and reactivate CD8þ T-cell with cytotoxic function(cytotoxic T lymphocytes [CTLs]).3,4 A number of
clinical trials have since shown that anti–PD-1 therapy
is effective in the treatment of various solid and he-
matologic malignancies including NSCLC. The response
rate of NSCLC to anti–PD-1 monotherapy is approxi-
mately 20%; therefore, response biomarkers have been
extensively investigated.4-8 Although biomarkers such
as tumor PD-L1 expression (tumor proportion score
[TPS]), tumor mutation burden (TMB), microsatellite
instability, T cell infiltration, and circulating PD-
1þCD8þ T cell are described, these markers are not so
useful and convenient due to the reliability, cost, and
time demands.4,5,7-9
Melanoma antigen-1 (MAGE-1, renamed MAGE-A1) of
cancer-testis (CT) antigen was discovered as the first
human tumor antigen, and hundreds of CT antigens have
since been identified.10,11 MAGE-A family members and
New York esophageal squamous cell carcinoma-1 (NY-
ESO-1) are broadly expressed in various human malig-
nancies, and MAGE-A1, MAGE-A3, NY-ESO-1, SSX, and
XAGE1 among CT antigens elicit spontaneous T cell and
humoral immune responses in cancer patients. NY-ESO-1
has been extensively investigated as a target of cancer
vaccines and T-cell therapy because it exhibits the
highest immunogenicity among CT antigens.10-18 XAGE1
is expressed in approximately 40% to 60% of lung ad-
enocarcinomas, and the XAGE1 serum Ab is a good
prognostic marker in advanced lung adenocarcinoma
patients, as we reported previously.14,19,20
In cancer patients with serum Ab against NY-ESO-1
and XAGE1, the antigen-specific CD4þ and CD8þ T cell
are frequently detected in peripheral blood.12,14,15 These
findings suggest that NY-ESO-1 and XAGE1 are major
immunodominant antigens and play important roles in
the immune surveillance of NSCLC. The serum Ab
positivity probably reflects the presence of activated
antigen-specific T cell and PD-1/PD-L1–mediated im-
mune suppression, suggesting good responses to anti–
PD-1 therapy (Supplementary Fig. 1). Accordingly, we
hypothesized that NY-ESO-1 and XAGE1 serum Abs have
potential as response biomarkers in anti–PD-1 therapy
for NSCLC, and conducted a prospective multicenter
study to verify this hypothesis.Materials and Methods
Study Design and Patients
This biomarker study was prospectively designed
and performed to explore whether NY-ESO-1 and
XAGE1 serum Abs predicted clinical responses and
further patient survival with anti–PD-1 therapy, ac-
cording to the Reporting Recommendations for
Tumour Marker Prognostic Studies criteria as listed in
the guideline.21 This study was approved by the
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School (number 2071-7; clinical study registry, UMIN-
CTR 000016678) and four medical centers in Japan,
and was performed in accordance with the Declaration
of Helsinki. For reference, we have investigated
expression and immune responses and monitoring
about CT antigens in human cancers including NSCLC
for a long time.15,17,19,20,22-24
Patients who have advanced NSCLC with metastatic/
recurrent and unresectable stages and postoperative
recurrence were consecutively enrolled into this study
from the above five medical centers between March
2016 and December 2018. Patient inclusion criteria
were good performance status 0-2, good organ function,
measurable lesions, and informed consent to this study.
Exclusion criteria were active multiple primary malig-
nancies and infections, autoimmune diseases, receiving
intensive immunosuppressive agents, and pregnancy.
Anti–PD-1 monotherapy with nivolumab or pem-
brolizumab was administered as a standard therapy for
these NSCLC patients in a first-line (TPS  50% at
diagnosis) or later setting according to government
approval in Japan. Before anti–PD-1 therapy, NY-ESO-1
and XAGE1 serum Abs were measured using enzyme-
linked immunosorbent assay (ELISA) by laboratory
scientists.
Patients in the discovery cohort were stratified by
their NY-ESO-1/XAGE1 serum Ab status for enrollment
in this observational study and were analyzed. Then,
when objective response rate (ORR) of anti–PD-1
monotherapy was 20% overall and at least 50% in the
Ab-positive patients, and when the Ab-positive pro-
portion was minimum 20% and maximum 25% in
advanced NSCLC patients, the required sample size was
75 and 56 in the independent validation cohort,
respectively. Finally, 75 patients with NSCLC were
enrolled in the validation study. It was calculated in a
priori power analysis for Fisher’s exact test with the
power level 0.8 and the significance level 0.05 by
G*Power calculator.25 The reasons for estimated ORR
20% and 50% were based on the results of prior
clinical trials and the ORR 50% in NSCLC of TPS greater
than or equal to 50% treated with pembrolizumab,
respectively, and the Ab-positive proportion 20% at
minimum and 25% at maximum were referred to
Supplementary Table 1.2,5 To assess the status of the
Ab response, sera from patients were collected within
2 months before anti–PD-1 therapy, and Ab titers were
measured. Clinical responses to anti–PD-1 therapy and
the Ab status were double-blinded with each other by
clinicians and laboratory scientists.
The primary and secondary endpoints in this study
were the ORR to anti–PD-1 therapy, and progression-free
survival (PFS) and overall survival (OS) after anti–PD-1therapy, respectively, according to the NY-ESO-1/XAGE1
serum Ab status.
Clinical Samples, Clinical Efficacy, and Survival
Analysis
Patients had consented to Institutional Review
Board–approved protocols permitting blood and tissue
sample collection and sequencing. Tumor tissues and
sera were obtained from all patients before anti–PD-1
therapy. Tumor tissues for whole-exome sequencing
were freshly frozen material from only the discovery
cohort patients before anti–PD-1 therapy. The EGFR
mutation (EGFRmt) or EML4-ALK-fusion was identified
by peptide nucleic acid–locked nucleic acid polymerase
chain reaction clamp and fluorescence in situ hybridi-
zation, respectively. As a negative control, sera from
nonmalignant donors were independently obtained
from previous study between 2015 and 2016.22
Target lesions at baseline were assessed according to
the Response Evaluation Criteria in Solid Tumors version
1.1 (RECIST v1.1), and the baseline sum of the longest
diameters for target lesions was recorded and used to
determine objective responses.26 Initial responses to
anti–PD-1 therapy were assessed by investigator-
assessed RECIST v1.1 criteria, and a complete response
(CR) and partial response (PR) were confirmed by a
repeat imaging occurring at least 4 weeks after the initial
identification of response.26 Unconfirmed responses
were considered stable disease (SD) or progressive dis-
ease (PD) dependent on the results of the second chest x-
ray or computed tomography scan. PD showed more
than 20% increase in the sum of diameters of target
lesions from baseline sum or the appearance of new le-
sions.26 All images were investigator-assessed by blin-
ded reviewers.
PFS rates were assessed according to RECIST v1.1
and PFS and OS were analyzed by the Kaplan-Meier
method. Differences in PFS and OS between patient
subgroups were analyzed using the Log-rank test, and
p values less than 0.05 were considered to be signifi-
cant. PFS and OS for living patients were censored at
the date of last known contact. The dates of PFS and OS
after anti–PD-1 therapy were updated as December
31, 2018.Antibody Responses to NY-ESO-1 and XAGE1
Ab responses to the NY-ESO-1 and XAGE1 pro-
teins were examined by ELISA, as we reported pre-
viously.20,27 The recombinant NY-ESO-1 and synthetic
XAGE1 protein (GL Biochemistry, Shanghai, China) (1
mg/mL) in a coating buffer was adsorbed onto 96-
well ELISA plates (Nunc, Roskilde, Denmark) and
incubated at 4C overnight. Plates were washed with
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calf serum/phosphate-buffered saline (200 mL/well)
at 37C for 1 hour. After washing, 100 mL of serially
diluted serum was added to each well and incubated
at 4C for 2 hours. After washing, alkaline phospha-
tase affinipure goat anti-human immunoglobulin G,
Fcg fragment-specific (1:5000) (Jackson Immuno
Research, West Grove, Pennsylvania) was added to
the wells and the plates were incubated at 37C for 1
hour. After washing and development (AttoPhos AP
fluorescent substrate system, Promega, Madison,
Wisconsin), absorbance was read at an excitation of
440/30 and emission of 560/40 with a gain of 50.
The cutoff value was based on the reactivity of
negative control sera from non-malignant donors (n ¼
60) and was defined as follows: the 95% confidence
interval (CI) upper limit optical density (OD) value of
the negative control serum pool. The extrapolated
titer of patient serum samples was defined as the
minimal dilution factor for which an O.D. greater than
the cutoff was examinable. The Ab response was
defined as positive for serum with extrapolated titers
exceeding or equal to 100 (100). The cutoff value of
greater than or equal to 100 for positive was deter-
mined by previous findings that NY-ESO-1/XAGE1–
specific T cells were frequently detected from cancer
patients with Ab titer greater than or equal to
100.15,28Immunohistochemistry for Immune
Microenvironment and CT Antigens
The tumor PD-L1 and major histocompatibility
(MHC)–class I expression, and CD8þ T cell, CD20þ B
cell, and CD163þ M2-macrophage infiltration in tumor
tissues before anti–PD-1 therapy were analyzed by
immunohistochemistry (IHC).22 Details of analysis
methods are fully provided in the Supplementary
Materials. Tumor NY-ESO-1 and XAGE1 antigen
expression before anti–PD-1 therapy were also
analyzed by IHC. Four-micrometer–thick sections were
deparaffinized with xylene and ethanol. Antigen
retrieval was performed by microwave heating in an-
tigen retrieval buffer (10 mM citrate buffer, pH 6.0)
with a pressure cooker for 10 minutes. After the
inactivation of endogenous peroxidase with 0.3% H2O2
for 15 and 5 minutes, respectively, specimens were
pre-incubated with serum-free blocking solution
(Nacalai Tesque and DakoCytomation, Kyoto, Japan) for
NY-ESO-1 and XAGE1, respectively. After washing, an
anti–NY-ESO-1 mouse monoclonal Ab (clone E978,
1:100, Invitrogen, Carlsbad, California) and USO 9-13
monoclonal Ab (2 mg/mL) were added and incubated at
4C and room temperature overnight for NY-ESO-1 andXAGE1, respectively. After washing, sample slides were
stained by the streptavidin-biotin complex (SimpleS-
tain MAX-PO kit; Nichirei, Tokyo, Japan), followed by a
reaction with 3, 30-diaminobenzidine in H2O2 and
counterstained with hematoxylin solution.
Whole-Exome Sequencing and Detection of
Tumor Somatic Mutations
DNA and RNA samples were prepared using AllPrep
DNA/RNA/miRNA Universal Kits (Qiagen, Hilden, Ger-
many) according to the manufacturer’s instructions.
Genomic DNA was converted to DNA libraries for DNA
sequencing using the SureSelect Target Enrichment
System Capture Process (Agilent Technologies, Santa
Clara, California). Details of analysis methods are fully
provided in the Supplementary Materials.
RNA Sequencing and Immunogenomic Analysis of
the Tumor Microenvironment
The characterization of the tumor immune microen-
vironment before anti–PD-1 therapy was further
analyzed by next-generation sequencing. The expression
of immune-related genes was extracted.29 The enrich-
ment of tumor-infiltrating lymphocytes was estimated
by a single sample Gene Set Enrichment Analysis
(ssGSEA) using gene sets provided by Charoentong
et al.30-32 Details of analysis methods are fully provided
in the Supplementary Materials.Statistical Analyses
Statistical analyses were performed with the two-
sided Mann–Whitney U test for two groups using
GraphPad Prism v.6 (Graphpad Prism Software, San
Diego, California) and IBM SPSS Statistics 23 for
Windows (IBM, New York, New York). In analyses of
the relationship between each parameter, Spearman’s
correlation analysis was performed. PFS and OS were
analyzed by the Kaplan-Meier method. Differences in
PFS and OS between patient subgroups were
analyzed using the Log-rank tests. To assess the
relationship between a factor and PFS and OS, uni-
variate and multivariate analyses were performed
using Cox’s proportional hazards regression model.
We previously reported in lung adenocarcinoma that
XAGE1 serum Ab was a good prognostic marker
regardless of EGFR status and that XAGE1 and
Galectin-9 were poor prognostic markers and tumor
PD-L1 expression and T-cell infiltration were likely
to be good prognostic ones.20,22 These factors rele-
vant to survival and the present study were inves-
tigated by a multivariate analysis. A multivariate
analysis was performed by all factors using Cox’s
regression analysis (backwards stepwise model).
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the threshold for significance was p less than 0.05.Results
Relationship Between Antibody Responses to NY-
ESO-1 and XAGE1 and Clinical Benefits of Good
Response and Long Survival With Anti–PD-1
Therapy for NSCLC
In the discovery cohort, 13 patients with NSCLC who
were treated with nivolumab were enrolled (Table 1),
and the median follow-up time from the registration was
3.6 months (range, 0.5 to 24.0 months). These patients
had previously been heavily treated with systemic
chemotherapy. The CT antibody, serum Ab against the
NY-ESO-1 and/or XAGE1 antigens, was positive in re-
sponders (CR and PR) and negative in nonresponders
(SD and PD) (Fig. 1A). Two patients with CR had one
each of NY-ESO-1 and XAGE1 Ab, whereas two of four
patients with PR had NY-ESO-1 Ab and the remaining
two had XAGE1 Ab. The CT antibody was not detected inTable 1. Patient Characteristics
Characteristics
Discovery
Cohort
(n ¼ 13)
Validation
Cohort
(n ¼ 75)
Sex
Male 12 (92) 55 (73)
Age, yr
Mean (SD) 64 (7) 68 (10)
Race Asian 13 (100) 75 (100)
Smoking status
Pack-years (SD) 77 (38) 41 (40)
Tumor type
Squamous cell carcinoma 6 (46) 21 (28)
Adenocarcinoma 7 (54) 50 (67)
Others 0 4 (5)
Disease stage
Metastatic/recurrent
or unresectable
13 (100) 59 (79)
Postoperative recurrence 0 16 (21)
Brain metastasis
Yes 4 (31) 20 (27)
Prior systemic regimens
Median (range) 3 (1-8) 1 (0-9)
Driver-mutation status
EGFR mutation 0 7 (9)
ALK translocation 1 (8) 0
Kras mutation 5 (38) —
ROS1 translocation 0 —
Unknown 0 9 (12)
CT antibody
Positive 6 (46) 17 (23)
Negative 7 (54) 58 (77)
Values shown are n (%) unless otherwise stated.
CT, cancer-testis antibody, serum antibody against NY-ESO-1 and/or XAGE1
antigen.patients who were nonresponders, and there was a sig-
nificant difference in the CT antibody titer between re-
sponders and nonresponders (Fig. 1A) (p < 0.01). The
best changes from the baseline of target lesions showed
marked differences between CT antibody-positive and
-negative patients (Fig. 1B). However, objective re-
sponses appeared to be associated with PD-L1 expres-
sion levels but not with the infiltration of various
immune cells, cytokines, chemokines, or tumor MHC-
class I expression levels analyzed by IHC and next-
generation sequencing (Fig. 1B, Supplementary Fig. 2).
CT antibody-positive patients obtained prolonged sur-
vival with anti–PD-1 therapy. Hazard ratios (HRs) of PFS
and OS between CT antibody-positive and -negative pa-
tients were 0.17 (95% CI: 0.04–0.66) (Fig. 2A) and 0.15
(95% CI: 0.04–0.60) (Fig. 2B), respectively.
In the independent validation cohort, 75 patients
with NSCLC were consecutively enrolled and received
nivolumab or pembrolizumab (Table 1), and the median
follow-up time from the registration was 7.3 months
(range, 0.5 to 24.0 months). The CT antibody was posi-
tive in 17 of 75 (23%) patients (Table 1, Fig. 1A),
comprising 10 XAGE1-positive Ab, 6 NY-ESO-1 Ab, and 1
with both Abs being positive (Fig. 1A). First-line anti–PD-
1 therapy was given in 2 (12%) and 7 (12%) of 17 CT
antibody-positive and 58 negative patients, respectively,
and 66 of 75 (88%) patients received anti–PD-1 therapy
after the second-line therapy, and 30 (40%) did after
third-line therapy (Fig. 2C). Eleven of 17 (65%; 5 CRs
and 6 PRs) CT antibody-positive patients responded to
anti–PD-1 therapy, in contrast to 11 of 58 (19%; 1 CR
and 10 PRs) CT antibody-negative patients (ORR 65% vs.
19%, p ¼ 0.0006), resulting in 29% (22 of 75) ORR in
the validation cohort (Fig. 1A, Table 2). The sensitivity
and specificity of CT antibody for response were 0.65
(95% CI: 0.38–0.86) and 0.81 (95% CI: 0.69–0.90),
respectively. A significant difference was observed in the
CT antibody titer between responders and non-
responders (Fig. 1A, p < 0.001), and the greatest changes
from the baseline of target lesions showed marked dif-
ferences between CT antibody-positive and -negative
patients (Fig. 1B). However, objective responses were
not associated with CD8þ T-cell infiltration or tumor PD-
L1 and MHC-class I expression levels in appropriate
available tissues before anti–PD-1 therapy (Fig. 1B). CT
antibody-positive patients obtained prolonged survival
with anti–PD-1 therapy; HRs of PFS and OS between CT
antibody-positive and -negative patients were 0.42 (95%
CI: 0.24–0.75) (Fig. 2A) and 0.21 (95% CI: 0.10–0.44)
(Fig. 2B), respectively, even after the second line or the
third line (Fig. 2C). In the multivariate analysis, response
markers were smoking (odd ratio ¼ 11, 95% CI: 1.0–
113), high PD-L1 expression (odd ratio ¼ 5.0, 95%: CI
1.0–26) and CT antibody positivity (odd ratio ¼ 9.6, 95%
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Figure 1. Relationship between antibody responses to NY-ESO-1 and XAGE1 cancer-testis (CT) antigens and clinical responses
with anti–programmed death 1 (PD-1) therapy. A, Extrapolated CT antibody (serum antibody against NY-ESO-1 and/or XAGE1
CT antigen) titers in the discovery (n ¼ 13) and validation (n ¼ 75) cohorts according to clinical responses with anti–PD-1
therapy. Patient sera were collected within 2 months before anti–PD-1 therapy, and CT antibody titers were measured by
enzyme-linked immunosorbent assay (ELISA) and defined as positive for serum with an extrapolated titer exceeding or equal
to 100 (100). Clinical responses were assessed according to the Response Evaluation Criteria in Solid Tumors version 1.1
(RECIST v1.1) guidelines. The numbers in parentheses indicate the number of CT antibody-positive patients/the number of
patients with complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). (*p < 0.01; ***p
< 0.001 by two-sided Mann-Whitney U test.) B, Target lesions and their size at baseline were assessed according to RECIST v
1.1. Best change from baseline in the sum of the longest diameters of target lesions in patients who had greater than or equal
to one evaluable post-baseline tumor assessment. Horizontal dotted-line represents the 20% threshold for declaring pro-
gression of target lesions and the -30% threshold for declaring response per RECIST v1.1. In the discovery and validation
cohorts, all patients with NSCLC were treated with nivolumab or pembrolizumab, and 6 of 13 NSCLC and 21 of 75 NSCLC
cases, respectively, in these cohorts were squamous cell carcinoma (S). Six patients in the discovery cohort had an EML4-ALK
fusion or Kras-mutation tumor, and 7 in the validation cohort had an EGFR-mutation tumor. Programmed death ligand 1 (PD-
L1) expression on tumor cells, CD8þ T-cell, B-cell, and M2-macrophage infiltration, and major histocompatibility (MHC) class I
and CTantigen expression levels in tumor tissues were evaluated by immunohistochemistry. A, adenocarcinoma; S, squamous
cell carcinoma; L, large cell carcinoma.
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significantly better predictive biomarker of PFS (HR ¼
0.4, 95% CI: 0.2–0.9) and OS (HR ¼ 0.2, 95% CI: 0.1–0.8)
after anti–PD-1 therapy (Table 2). Consequently, CT
antibody-positive patients in the validation cohort also
achieved clinical benefits of good response and long
survival with anti–PD-1 therapy, even though they were
heavily treated patients.
Relationships Among CT Antigen Expression, CT
Antibody, and Clinical Responses to Anti–PD-1
therapy
We investigated the relationship between NY-ESO-1/
XAGE1 expression levels and CT antibody titers in the
discovery and validation cohorts. Figure 3A shows
representative staining of tumor NY-ESO-1 and XAGE1protein. No apparent correlations between NY-ESO-1/
XAGE1 expression levels and CT antibody titers were
observed (Fig. 3B). Then, we investigated the relation-
ship between CT antibody titers before anti–PD-1 ther-
apy and tumor reduction rates after anti–PD-1 therapy,
resulting in a strong correlation between them (Fig. 3C)
(p < 0.0001). This indicates that CT antibody is useful
biomarker predicting responses to anti–PD-1 therapy.
Relationships Among the CT Antibody, Tumor
Missense-Mutation Burden (TMB), PD-L1
Expression, CD8 T-Cell Infiltration, and Clinical
Benefits With Anti–PD-1 Therapy for NSCLC
We evaluated TMB, tumor PD-L1 expression, CD8þ T-
cell, B-cell, and M2-macrophage infiltration, and tumor
MHC-class I expression levels in the discovery cohort
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Figure 2. Kaplan-Meier curves for the progression-free survival (PFS) and overall survival (OS) of patients according to
cancer-testis (CT) antibody status in the discovery and validation cohorts after anti–programmed death 1 (PD-1) therapy.
A, Kaplan-Meier curves for the PFS of patients according to the CT antibody (serum antibody against NY-ESO-1 and/or XAGE1
CT antigen) status in the discovery and validation cohorts after anti–PD-1 therapy. PFS was calculated from the date of anti–
PD-1 therapy to the date of disease progression or death from any cause. Hazard ratio (HR) for PFS of CT antibody-positive
patients, as compared to that of -negative patients, was calculated with Cox regression analysis, and 95% confidence interval
(CI) was shown. B, Kaplan-Meier curves for the OS of patients according to the CT antibody status in the discovery and
validation cohorts after anti–PD-1 therapy. OS was calculated from the date of anti–PD-1 therapy to the date of death from
any cause. HR for OS of CT antibody-positive patients, as compared to that of negative patients, was calculated with Cox
regression analysis, and 95% CI was shown. C, Kaplan-Meier curves for the PFS and OS of patients according to the CTantibody
status in the validation cohorts after the second line (n ¼ 66) and the third line (n ¼ 30) anti–PD-1 therapy. PFS and OS were
calculated as described above. HR for PFS and OS of CT antibody-positive patients, as compared to those of -negative pa-
tients, was calculated with Cox regression analysis, and 95% CI was shown. Ab, antibody; pos, positive; neg, negative.
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sentative staining was shown in Supplementary Fig. 3.
ORR with anti–PD-1 therapy appeared to be associated
with a high CT antibody titer (100%), TMB (75%), and
PD-L1 expression (83%) (Fig. 4B), but not with CD8þ T-
cell, B-cell, and M2-macrophage infiltration or tumor
MHC-class I expression levels (Fig. 1B). PFS, OS, and ORR
according to TMB and the PD-L1 expression status, and
the combination of these two were analyzed, showing
better PFS and ORR with high TMB and PD-L1 expres-
sion than with low TMB and PD-L1 expression
(Supplementary Fig. 4).
We investigated whether the combination of the CT
antibody and tumor PD-L1 expression or CD8þ T-cell
infiltration has potential as a biomarker for clinical re-
sponses with anti–PD-1 therapy in 72 available tumor
tissues (Supplementary Fig. 5). Regardless of the PD-L1expression status, CT antibody-positive patients had
higher ORR and longer PFS and OS than CT antibody-
negative patients. Furthermore, regardless of CD8þ T-
cell infiltration, the former had higher ORR than the
latter. For example, a patient who had lung adenocar-
cinoma with XAGE1 Ab and EML-4/ALK-fusion achieved
CR with anti–PD-1 therapy, and the marked intratumor
infiltration of lymphocytes was observed after anti–PD-1
therapy (Supplementary Fig. 6). These results indicate
that the CT antibody, even alone, is an independently
useful biomarker for predicting clinical benefits of good
response and long survival with anti–PD-1 therapy.Discussion
The present study showed that NSCLC patients with
NY-ESO-1 and/or XAGE1 Ab obtained the significant
Table 2. Objective Response Rate, Progression-Free Survival, and Overall Survival With Anti–Programmed Death 1 Therapy, According to Patient Characteristics and
Immunological Status
Characteristics
No. of
Patients
With CR
or PR/Total
CR or PR Rate
(95% CI) %
Odds Ratio for
CR or PR
(95% CI)
Median
PFS
p
Value
Univariate
Analysis for
PFS
HR (95% CI)
Multivariate
Analysis for
PFS
HR (95% CI)
Median
OS
p
Value
Univariate
Analysis for
OS
HR (95% CI)
Multivariate
Analysis for
OS
HR (95% CI)
Sex
Male 16/55 29 (18 to 43) — 2.8 0.58 1.0 (0.6 to 1.9) — NR 0.56 2.1 (0.9 to 4.9) —
Female 6/20 30 (12 to 54) 4.3 18.4
Age, yr
＜65 7/24 29 (13 to 51) — 1.9 0.32 1.3 (0.7 to 2.3) — 12.5 0.25 1.5 (0.8 to 3.0) —
 65 15/51 29 (17 to 44) 3.6 18.4
Smoking status
Current or former
smoker
17/53 32 (20 to 46) 11 (1.0 to 113) 3.3 0.37 0.7 (0.4 to 1.3) 0.4 (0.2 to 0.8) 18.4 0.72 1.1 (0.6 to 2.4) 0.8 (0.3 to 2.1)
Never-smoker 5/22 23 (8 to 45) 2.8 14.1
Tumor type
Squamous
cell carcinoma
6/21 29 (11 to 52) — 2.8 0.97 1.3 (0.7 to 2.4) — 8.3 0.13 1.8 (0.8 to 3.7) —
Non-squamous cell
carcinoma
16/54 30 (18 to 44) 3.2 16.0
Disease stage
Metastatic/
recurrent
or unresectable
18/59 31 (19 to 44) 4.1 (0.5 to 34) 2.8 0.72 1.2 (0.6 to 2.2) 0.8 (0.4 to 1.9) 14.0 0.84 1.1 (0.5 to 2.5) 0.5 (0.2 to 1.5)
Postoperative
recurrence
4/16 25 (7 to 52) 3.3 14.1
Brain metastasis
Present 6/20 30 (12 to 54) 0.3 (0.04 to 1.6) 2.4 0.34 1.3 (0.7 to 2.3) 2.2 (1.0 to 4.6) 5.2 0.09 1.8 (0.9 to 3.7) 5.2 (2.0 to 13)
None 16/55 29 (18 to 43) 3.3 14.1
Regimen line
First or second line 15/45 33 (20 to 49) — 3.3 0.35 0.8 (0.5 to 1.4) — 14.0 0.91 1.0 (0.5 to 1.9) —
Later line 7/30 23 (10 to 42) 2.7 14.1
Driver mutation
status (EGFR)
Positive 2/7 29 (4 to 71) 6.3 (0.2 to 198) 4.6 0.50 1.3 (0.6 to 2.9) 0.7 (0.2 to 2.6) NR 0.31 0.5 (0.2 to 1.8) 0.5 (0.1 to 3.1)
Negative 18/59 31 (19 to 44) 3.2 14
CD8þ T-cell
infiltration
High 9/28 32 (16 to 52) — 2.3 0.67 1.1 (0.6 to 2.0) — 14.0 0.72 0.9 (0.4 to 1.9) —
Low 10/31 32 (17 to 51) 3.2 14.1
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December 2019 Predictive Biomarkers for Anti-PD-1 Therapy of NSCLC 2079clinical benefits of high ORR and long PFS and OS with
anti–PD-1 therapy, as compared with the Ab-negative
patients. Additionally, Ab titers highly correlated with
tumor reduction rates in anti–PD-1 therapy. Thus, our
results suggest that strong immune surveillance was
present in CT antibody-positive NSCLC patients who
responded well to anti–PD-1 therapy, reversing immune
suppression or tolerance. Therefore, NY-ESO-1 and
XAGE1 Ab are considered to be convenient and useful
biomarkers predicting clinical benefits of good response
and long survival in anti–PD-1 therapy for NSCLC. Our
novel findings in NSCLC would be extended to biomarker
study in immunotherapies of other cancers because NY-
ESO-1 is broadly expressed in many types of malignancy.
Here, we for the first time reported a strong cor-
relation between NY-ESO-1 and XAGE1 Ab titers and
tumor reduction rates with anti–PD-1 therapy for
NSCLC. Similarly, Yuan et al.28 reported a good corre-
lation between NY-ESO-1 Ab titers and clinical re-
sponses and a close association between Ab-positivity
with CD8þ T-cell response and long survival, with
anti-CTL antigen 4 (CTLA-4) therapy in melanoma. In
addition, they addressed a close association between
NY-ESO-1–specific Ab and CD8þ T cell in patients who
were responders. We also detected NY-ESO-1–specific
CD8þ T cell from peripheral blood of patient with CR
after anti–PD-1 therapy (data not shown). Thus, it is
speculated that CT antibody titers reflect cytotoxic
activity levels of CT antigen-specific CD8þ T cell.
In this study, many patients had been heavily treated
with conventional chemotherapy; however, it is unlikely
that CT antibody is associated with sensitivity to
chemotherapy. Rather, CT antibody is considered to be a
specific response biomarker for anti–PD-1 and –CTLA-4
therapy. There are few clinical reports focusing on CT
antibody itself or the relationship between the antibody
and cancer therapy, although Yuan et al.28 showed good
correlations between NY-ESO-1 Ab and clinical benefits
with anti–CTLA-4 therapy in melanoma as described
above. These results indicate the presence of activated
CT antigen-specific CD8þ T cell and checkpoint
molecule–mediated strong immunosuppression in CT
Ab-positive patients, reflecting good responses to
checkpoint inhibitors even in patients heavily treated
with chemotherapy. In the near future, these issues
would be investigated in detail.
NY-ESO-1 and XAGE1 Ab were strongly associated
with high response rates in anti–PD-1 therapy for
NSCLC; however, the well-known biomarkers of tumor
PD-L1 expression and TMB were also associated with
better responses in the present study, as reported
previously.4-8 However, no relationship was noted be-
tween these Ab and the two biomarkers, indicating that
these Ab are independent biomarkers in NSCLC. On the
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Figure 3. Relationships between cancer-testis (CT) antigen expression levels and the serum CTantibody titers, and between
CTantibody titers and clinical responses with anti–programmed death 1 (PD-1) therapy. A, Typical immunostaining for NY-ESO-
1 (left) and XAGE1 (right) protein in tumor cells. NY-ESO-1 and XAGE1 antigen are stained in the whole cells and nucleus,
respectively. B, Relationship between NY-ESO-1/XAGE1 expression levels and the CT antibody (serum antibody against NY-
ESO-1 and/or XAGE1 CT antigen) titers. The expression levels are represented as immunohistochemistry (IHC) score calcu-
lated by D (distribution)  I (intensity) in staining. Distribution (D) is scored as 0, 0%; 25, 1 ¼ 25%:50, 26w50%; 75, 51w75%;
100, 76w100%. Intensity (I) is scored as 0, no signal; 1, weak; 2, moderate; 3, marked. C, Relationship between the CT
antibody titers before anti–PD-1 therapy and tumor reduction rates after anti–PD-1 therapy was analyzed by using Spearman’s
correlation analysis. Best change from baseline in sum of the longest diameters of target lesions in patients who had greater
than or equal to one evaluable post-baseline tumor assessment was calculated. Target lesions and their size were assessed
according to Response Evaluation Criteria in Solid Tumors, version 1.1.
2080 Ohue et al Journal of Thoracic Oncology Vol. 14 No. 12other hand, neither CD8þ T-cell, B-cell, and M2-
macrophage infiltration nor tumor MHC-class I expres-
sion levels were associated with clinical responses.
Many clinical trials on anti–PD-1 monotherapy for
NSCLC have shown a correlation between tumor PD-L1
expression and ORR regardless of the antibodies used
for PD-L1 staining, and ORRs were approximately
20%.4-6,8,33 Notably, the ORR of 29% in our validation
cohort (n ¼ 75) was similar to those in previous clinical
trials on anti–PD-1 therapy, indicating that our results
are not accidental and notable. Therefore, NY-ESO-1 and
XAGE1 Ab need to be incorporated into stratification
factors in future clinical trials on immune-checkpoint
therapy for NSCLC.
NSCLC expresses multiple CT antigens such as NY-ESO-
1, MAGE-A, SSX, and GAGE family members at the protein
or mRNA level, which may be related to tumor progres-
sion10-14,22; however, their functions are not fully
known.10-12 In the present study, NY-ESO-1 and XAGE1
protein expressionwas detected in17 (23%) and28 (37%)
of 75 patients with available tumor tissues, respectively;
however, CT antigen expression levels in biopsy specimensdid not correlate with CT antibody titers before anti–PD-1
therapy. Extensive clinicopathologic studies have shown
that CT antigen expression in NSCLC is closely associated
with the male sex, advanced diseases (stages III and IV),
poor survival, and increased tumor burden.14 Approxi-
mately 20% of NSCLC cases reportedly express NY-ESO-1
mRNA, which correlate with protein expression levels.34-
36 Among them, lung squamous cell carcinoma is re-
ported to frequently express the NY-ESO-1 antigen with
serum Ab in advanced stages, which is consistent with our
results for squamous cell carcinoma.14 NY-ESO-1–specific
CD8þ T cell has been isolated from most patients with NY-
ESO-1 Ab, and we also isolated NY-ESO-1–specific CD8þ T
cell after anti–PD-1 therapy (data not shown).12,14
Regarding XAGE1, approximately 40% to 60% of lung ad-
enocarcinomas specifically express XAGE1, the Ab ofwhich
is frequently detected in advanced stages, as we reported
previously.14,15,19,20,37 Notably, NY-ESO-1 and XAGE1
among many CT antigens frequently elicit spontaneous
CD4þ and CD8þ T cell and humoral immune responses in
patients with advanced NSCLC, suggesting that these anti-
gens are highly immunogenic and strongly related to the
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Figure 4. Relationship between four predictive biomarkers
and clinical responses with anti–programmed death 1 (PD-1)
therapy. A, Relationships among the CT antibody (serum
antibody against NY-ESO-1 and/or XAGE1 CT antigen), tumor
missense-mutation burden, programmed death ligand 1 (PD-
L1) expression, CD8þ T-cell infiltration, and clinical re-
sponses with anti–PD-1 therapy in the discovery cohort (n ¼
13). Clinical responses were assessed according to Response
Evaluation Criteria in Solid Tumors, version 1.1 guidelines.
B, Objective response rates were shown according to high
and low levels of the above four factors. High levels of each
factor were defined for titer greater than or equal to 100 for
the CT antibody, greater than or equal to 178 (median value)
nonsynonymous single nucleotide variants for mutations,
greater than or equal to score 2 (mean value) for PD-L1
expression, and greater than or equal to 10% (mean value)
for %CD8þ T cell, and a low level was less than the high
level values. CT antigen-specific CD4þ and CD8þ T cells
were frequently detected in patients with CT antibody
titer greater than or equal to 100. CR, complete
response; PR, partial response; SD, stable disease; PD, pro-
gressive disease.
December 2019 Predictive Biomarkers for Anti-PD-1 Therapy of NSCLC 2081immune surveillance of NSCLC.14,15,23,37 Thus, NY-ESO-1
and XAGE1 immunity in NSCLC are promising targets for
immune-checkpoint therapy reversing immune
suppression.
Our NSCLC patients with NY-ESO-1 and XAGE1 Ab
responded particularly well to anti–PD-1 therapy. Oneexplanation for this result is the high immunogenicity of
the NY-ESO-1 and XAGE1 antigens in NSCLC, as described
above. Another reason is that some NSCLC patients’ T cells
simultaneously recognize multiple tumor antigens
including CT antigens, as previously reported, and that
anti–PD-1 and –CTLA-4 therapy elicited neoantigen-
specific CD8þ T-cell responses in NSCLC and melanoma,
respectively.13,14,38-40 Consequently, many antigens are
considered to elicit antigen-specific CD8þ T-cell responses
destroying tumor cells. However, all tumor antigens do not
always elicit CD8þ T-cell responses; a previous study re-
ported that mutant p53 peptides elicited CD4þ T cell and
humoral, but not CD8þ T-cell responses.41 The immuno-
genicity of each tumor antigen expressed inNSCLCmust be
investigated in more detail for future immunotherapies.
Although this study only included 88 NSCLC patients,
two of seven patients with EGFRmt and XAGE1 Ab ach-
ieved CR and PR with anti–PD-1 therapy, and only one
lung adenocarcinoma with EML4-ALK fusion and XAGE
Ab had CR (Supplementary Fig. 5). These results indicate
that XAGE1 Ab-positive NSCLC with EGFRmt or EML4-
ALK-fusion responds to anti–PD-1 therapy. Several clin-
ical trials on anti–PD-1 therapy have shown that NSCLC
with EGFRmt usually does not have the clinical benefits
of a better response and survival with anti–PD-1 ther-
apy.7,42 This may be because these NSCLC patients were
non- or light smokers with low TMB.39,43 Accordingly,
EGFRmt may be a poor-response biomarker in anti–PD-1
therapy for NSCLC, whereas NY-ESO-1 and XAGE1 Ab
may be good-response markers because NY-ESO-1 and
XAGE1 are highly immunogenic in NSCLC, as we
described above. NY-ESO-1 and XAGE1, as well as driver
mutations of EGFRmt and EML4-ALK fusion, are tumor
progression factors; however, CT antigens are highly
immunogenic, whereas driver mutations may not be
in NSCLC patients. Thus, NSCLC with EGFRmt may
be divided into two types: CT antibody-positive and
-negative, and CT antibody-positive NSCLC with EGFRmt
may obtain clinical benefits with anti–PD-1 therapy, as
shown here. This issue must be clarified in clinical trials
on NSCLC with EGFRmt as soon as possible.
The limitations of the present study were the small
number of patients included, the short follow-up time
after anti–PD-1 therapy, and many analyses of small bi-
opsy specimens. Larger clinical studies are needed to
confirm the usefulness of the CT antibody as a predictive
biomarker of the clinical benefits of good response and
long survival associated with anti–PD-1 therapy. Now we
are planning a large-scale study of patients with NSCLC.
In conclusion, patients who have NSCLC with
NY-ESO-1 and XAGE1 Abs obtained significant clinical
benefits of good response and long survival with anti–
PD-1 therapy, and Ab titers correlated well with tumor
reduction rates after anti–PD-1 therapy. NY-ESO-1 and
2082 Ohue et al Journal of Thoracic Oncology Vol. 14 No. 12XAGE1 Ab are predictive biomarkers of clinical benefits
with anti–PD-1 therapy for NSCLC, and must be incor-
porated into future clinical trials on immune checkpoint
inhibitors as stratification factors.
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